Lycia Therapeutics Raises $75 Million in Oversubscribed Financing and Strengthens Leadership Team with Appointment of Chief Financial Officer and General Counsel

Financing co-led by Janus Henderson Investors and Balyasny Asset Management, with participation from Adage Capital Management, HBM Healthcare Investments, OrbiMed and continued support from existing investors Proceeds to support advancement of Lycia’s LYTAC pipeline, including LCA-0061 for food allergy and LCA-0321 for Graves’ disease, to early clinical POC Amy Bachrodt appointed Chief Financial Officer; Karen […] The post Lycia Therapeutics Raises $75 Million in Oversubscribed Financing and Strengthens Leadership Team with Appointment of Chief Financial Officer and General Counsel appeared fi